<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20784" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dysbetalipoproteinemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Javvaji</surname>
            <given-names>Abhiram</given-names>
          </name>
          <aff>Arnot Ogden Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Can</surname>
            <given-names>Ahmet S.</given-names>
          </name>
          <aff>Lake Erie College of Osteopathic Medicine (LECOM)</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Saurabh</given-names>
          </name>
          <aff>Guthrie Robert Packer Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abhiram Javvaji declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmet Can declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Saurabh Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20784.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Dysbetalipoproteinemia, also known as familial dysbetalipoproteinemia, hyperlipoproteinemia type III (HLP3), or broad &#x003b2; disease, is a genetic&#x000a0;abnormality in apolipoprotein E2 (apoE) that causes impaired lipoprotein metabolism. This lipoprotein metabolic abnormality promotes fatty deposit accumulation on arterial walls,&#x000a0;elevated serum triglycerides and total cholesterol, and the development of palmar xanthomas. Dysbetalipoproteinemia is associated with complications, including coronary artery disease and peripheral vascular disease.&#x000a0;Establishing the presence of the dysbetalipoproteinemia phenotype and the&#x000a0;<italic toggle="yes">APOE</italic>&#x000a0;genotype, which are the underlying etiologies of dysbetalipoproteinemia, is essential for diagnosis. The management of&#x000a0;dysbetalipoproteinemia primarily consists of&#x000a0;dietary lipid restriction and pharmacologic therapy with statins and fibrates. Clinicians should monitor patients during treatment using non-high-density lipoprotein cholesterol (non-HDL-C) testing to ensure that atherogenic lipoproteins are well controlled.&#x000a0;This activity for healthcare professionals aims to enhance learners' competence in selecting appropriate diagnostic tests, managing&#x000a0;dysbetalipoproteinemia, and fostering effective interprofessional teamwork to improve outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of familial dysbetalipoproteinemia disease.</p></list-item><list-item><p>Implement the recommended evaluation of familial dysbetalipoproteinemia.</p></list-item><list-item><p>Determine the proper treatment&#x000a0;strategy for patients with dysbetalipoproteinemia.</p></list-item><list-item><p>Collaborate with interprofessional healthcare team members to improve outcomes for patients with dysbetalipoproteinemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20784&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20784">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20784.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Dysbetalipoproteinemia, also known as familial dysbetalipoproteinemia (FD), hyperlipoproteinemia type III (HLP3), or broad &#x003b2; disease, is a genetic lipid disorder characterized by increased accumulation of triglyceride-rich remnant lipoproteins. The accumulation of lipoproteins&#x000a0;is due to impaired remnant clearance. Most patients with&#x000a0;dysbetalipoproteinemia are homozygous for the <italic toggle="yes">apolipoprotein E2</italic> (<italic toggle="yes">APOE)</italic>&#x000a0;gene. Additionally, FD is associated with poor adherence of apolipoprotein E to the LDL receptors. Although FD is an autosomal recessive condition in most cases, 10% of cases are due to autosomal dominant mutations. This lipoprotein metabolic abnormality promotes fatty deposit accumulation on arterial walls,&#x000a0;elevated serum triglycerides and total cholesterol, and the development of palmar xanthomas.<xref ref-type="bibr" rid="article-20784.r1">[1]</xref> Dysbetalipoproteinemia is associated with complications, including coronary artery disease and peripheral vascular disease.&#x000a0;FD has a 10-fold increased risk for premature coronary artery disease compared to population-based controls.<xref ref-type="bibr" rid="article-20784.r2">[2]</xref>&#x000a0;</p>
        <p>Establishing the presence of the dysbetalipoproteinemia phenotype and the&#x000a0;<italic toggle="yes">APOE</italic>&#x000a0;genotype, which are the underlying etiologies of dysbetalipoproteinemia, is essential for diagnosis. The management of&#x000a0;dysbetalipoproteinemia primarily consists of&#x000a0;dietary lipid restriction and pharmacologic therapy with statins and fibrates. Clinicians should monitor patients during treatment using non&#x02013;high-density lipoprotein cholesterol (non&#x02013;HDL-C) testing to ensure that atherogenic lipoproteins are well controlled.<xref ref-type="bibr" rid="article-20784.r1">[1]</xref></p>
      </sec>
      <sec id="article-20784.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Familial dysbetalipoproteinemia (FD) is caused by a genetic mutation in the <italic toggle="yes">apolipoprotein E</italic> (<italic toggle="yes">APOE</italic>) gene, leading to <italic toggle="yes">Apo E2/E2</italic> homozygotes.&#x000a0;The most common isoform of <italic toggle="yes">APOE</italic>&#x000a0;is <italic toggle="yes">APOE</italic><italic toggle="yes">3</italic>. The primary cause of dysbetalipoproteinemia is the presence of another isoform of <italic toggle="yes">APOE</italic>&#x000a0;called <italic toggle="yes">APOE</italic><italic toggle="yes">2</italic>, which differs from&#x000a0;<italic toggle="yes">APOE</italic><italic toggle="yes">3</italic> by a single amino acid substitution of cysteine for arginine at position 158.<xref ref-type="bibr" rid="article-20784.r3">[3]</xref></p>
        <p>Dysbetalipoproteinemia primarily results in the accumulation of remnant lipoprotein. <italic toggle="yes">ApoE</italic> is found on triglyceride-rich lipoprotein particles like chylomicrons, very low-density lipoproteins (VLDL), and intermediate-density lipoproteins (IDL). It mediates their catabolism by binding to receptors in the liver. The presence of <italic toggle="yes">APOE</italic><italic toggle="yes">2</italic> isoform on these triglyceride-rich particles leads to impaired binding of lipoprotein particles to lipoprotein receptors, such as LDL receptors (LDLR), LDLR-related proteins (LRP), and heparan sulfate proteoglycans (HSPG).</p>
        <p>HSPG contains a single transmembrane polypeptide strand (core protein) called heparan sulfates, to which sugar polymers are attached.<xref ref-type="bibr" rid="article-20784.r4">[4]</xref> They capture the lipoproteins and other ligands. Out of many HSPG species, syndecan 1 HSPG-R is involved in remnant clearance, found in the space of Disse, where the remnant particle clearance occurs. This impaired binding results in the defective removal of chylomicrons and VLDL remnants, leading to their accumulation in circulation, which eventually causes premature atherosclerosis.</p>
      </sec>
      <sec id="article-20784.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The&#x000a0;<italic toggle="yes">APOE</italic>&#x000a0;gene locus has 3 main variants, namely E2, E3, and E4, which results in 3 homozygous (E2E2, E3E3, and E4E4) and 3 heterozygous (E2E3, E3E4, and E4E2) genotypes. The E3E3 is the most frequent APOE genotype in humans; hence, the E3E3 form is considered the wild type.<xref ref-type="bibr" rid="article-20784.r5">[5]</xref>&#x000a0;Either homozygous apo E2/E2 genotype, which is more common, or heterozygosity apo E3-Leiden and apoE2 (Lys1463Gln), which are rare, must be present to have a phenotypical presentation or elevated triglyceride (TG), and total cholesterol.<xref ref-type="bibr" rid="article-20784.r6">[6]</xref><xref ref-type="bibr" rid="article-20784.r7">[7]</xref><xref ref-type="bibr" rid="article-20784.r8">[8]</xref>&#x000a0;Autosomal recessive mutations are more common. Autosomal dominant mutations cause 10% of familial dysbetalipoproteinemia cases.<xref ref-type="bibr" rid="article-20784.r9">[9]</xref></p>
        <p>The prevalence of dysbetalipoproteinemia varies depending on the definition used to determine the condition. Previous studies differed in their inclusion or exclusion of E2/E2 genotype, autosomal dominant mutations, VLDL-cholesterol/plasma TG ratio &#x0003e;0.30 on gel electrophoresis, TG/ApoB ratio, and total cholesterol/Apo B ratio. One study definition states if a patient has a total cholesterol level of more than the 90th percentile and an E2/E2 genotype, they are diagnosed with dysbetalipoproteinemia. The prevalence demonstrated in this study was 0.1% or 1 in 1000 of the general population.<xref ref-type="bibr" rid="article-20784.r10">[10]</xref><xref ref-type="bibr" rid="article-20784.r11">[11]</xref></p>
        <p>In contrast, another earlier stated a VLDL-cholesterol/plasma TG ratio &#x0003e;0.30 on gel electrophoresis was needed to diagnose the disease. This study had a prevalence of 0.4% in men and 0.2% in women.<xref ref-type="bibr" rid="article-20784.r12">[12]</xref>&#x000a0;Another study found a similar prevalence among CAD patients at 0.7% in controls and 2.7% in those with CAD. However, the first study did not include autosomal dominant mutations, excluding a portion of type III dysbetalipoproteinemia. If these patients had been included, the prevalence of FD would be 0.12% or 1 in 825. The second study did not include the E2/E2 genotype or autosomal dominant patients. Another study that used the measurement of apoB/TC with a cut-off threshold of &#x0003c;0.15 as the diagnostic indicator determined the prevalence of FD was 2.7%.&#x000a0;However, another study using a similar indicator, though TG was included, reported a prevalence of 1.7%.<xref ref-type="bibr" rid="article-20784.r13">[13]</xref><xref ref-type="bibr" rid="article-20784.r14">[14]</xref><xref ref-type="bibr" rid="article-20784.r13">[13]</xref>&#x000a0;These studies included patients with E2/E2 but not those with autosomal dominant mutations.</p>
        <p>In the homozygous <italic toggle="yes">APOE</italic>2 genotype, there are more hypolipidemic rather than hyperlipidemic.<xref ref-type="bibr" rid="article-20784.r15">[15]</xref>&#x000a0;Accumulation of remnant occurs when there is an accompanying secondary genetic or acquired defect, including decreased remnant clearance, decreased LDL receptor activity, and increased VLDL production.<xref ref-type="bibr" rid="article-20784.r3">[3]</xref>&#x000a0;The interaction of environmental and genetic factors is required for phenotypic expression.<xref ref-type="bibr" rid="article-20784.r16">[16]</xref><xref ref-type="bibr" rid="article-20784.r17">[17]</xref></p>
        <p>Men and postmenopausal women are more predisposed to the condition than premenopausal women as they do not have the benefit of estrogen. Estrogen affects the lipolytic process and LDL receptor expression.<xref ref-type="bibr" rid="article-20784.r3">[3]</xref>&#x000a0;Dysfunctional lipolytic processing of remnants with increased VLDL production causes hypertriglyceridemia, and impaired receptor clearance leads to hypercholesteremia.</p>
      </sec>
      <sec id="article-20784.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with dysbetalipoproteinemia may have a variety of clinical presentations. Approximately 50% of patients develop cutaneous xanthomas, most commonly the eruptive or palmar crease type of xanthomas.<xref ref-type="bibr" rid="article-20784.r18">[18]</xref>&#x000a0;Tuberous xanthomas, tendon xanthomas, and xanthelasma are common in most mixed familial dyslipidemia disorders but not specific to familial dysbetalipoproteinemia.<xref ref-type="bibr" rid="article-20784.r19">[19]</xref>&#x000a0;Palmar xanthomas and tuberous xanthomas&#x000a0;are more commonly seen when levels are more than 1000. Once treatment is initiated, palmar crease xanthomas resolve with time. Some patients may first present with signs of premature atherosclerosis (eg, angina or acute coronary syndrome) or pancreatitis with hypertriglyceridemia.<xref ref-type="bibr" rid="article-20784.r20">[20]</xref></p>
        <p>The most common types of cardiovascular disease in patients with familial dysbetalipoproteinemia are peripheral artery disease (PAD) and coronary artery disease (CAD).&#x000a0;A cross-sectional study of 305 European subjects demonstrated a 19% prevalence of CAD, 11% prevalence of PAD, and 4% of cerebrovascular disease in FD patients.<xref ref-type="bibr" rid="article-20784.r21">[21]</xref>&#x000a0;Insulin resistance and obesity are also common presentations.<xref ref-type="bibr" rid="article-20784.r22">[22]</xref></p>
        <p>Patients with coronary artery disease secondary to dysbetalipoproteinemia generally present in the same manner as any other patient with CAD. A common symptom is chest pain with exertion or at rest. Less frequent symptoms include fatigue, exertional shortness of breath, peripheral edema, and transient nonspecific chest discomfort.<xref ref-type="bibr" rid="article-20784.r23">[23]</xref>&#x000a0;Patients may have peripheral artery disease without symptoms or with associated symptoms, including intermittent claudication, acute limb ischemia, or chronic limb ischemia.<xref ref-type="bibr" rid="article-20784.r24">[24]</xref></p>
      </sec>
      <sec id="article-20784.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Establishing the presence of the dysbetalipoproteinemia phenotype and the <italic toggle="yes">APOE</italic> genotype, which are the underlying etiologies of dysbetalipoproteinemia, is essential for diagnosis.<xref ref-type="bibr" rid="article-20784.r1">[1]</xref>&#x000a0;Positive clinical findings (eg, palmar xanthomas and tuberous xanthomas) and an initial fasting lipid profile demonstrating increased total cholesterol and triglyceride levels raise clinical suspicion of FD. Levels of total cholesterol and triglyceride (TG) levels are usually within the range of 300 to 1000 mg/dL with an approximately similar range or disproportionally high triglyceride or low low-density&#x000a0;lipoprotein cholesterol (LDL-C) levels as opposed to total cholesterol (TC).<xref ref-type="bibr" rid="article-20784.r25">[25]</xref>&#x000a0;Genotyping with an evaluation of&#x000a0;<italic toggle="yes">APOE</italic>&#x000a0;with the E2/E2 genotype is usually needed for diagnosis, and in cases of autosomal dominant inheritance, full&#x000a0;<italic toggle="yes">APOE</italic>&#x000a0;sequencing may be required.<xref ref-type="bibr" rid="article-20784.r26">[26]</xref><xref ref-type="bibr" rid="article-20784.r27">[27]</xref>However, with lipid studies alone, FD can not be differentiated from other <italic toggle="yes">APOE</italic>&#x000a0;genotype variant abnormalities that cause dyslipidemia (eg, familial hypercholesterolemia, hypertriglyceridemia, or lipoprotein glomerulopathy). Therefore,&#x000a0;the dysbetalipoproteinemia phenotype must be determined as well. The standard studies utilized are&#x000a0;ultracentrifugation and polyacrylamide gradient gel electrophoresis (PGGE).<xref ref-type="bibr" rid="article-20784.r28">[28]</xref> In areas where these diagnostic studies are unavailable, apoB testing can be utilized to assess for the dysbetalipoproteinemia phenotype. The following methods and thresholds, which all have a relatively high sensitivity and specificity, may be used to diagnose dysbetalipoproteinemia.<xref ref-type="bibr" rid="article-20784.r1">[1]</xref><xref ref-type="bibr" rid="article-20784.r29">[29]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Ultracentrifugation:&#x000a0;
<list list-type="bullet"><list-item><p>VLDL-cholesterol/VLDL-triglyceride (TG) molar ratio: &#x0003e;0.97</p></list-item><list-item><p>VLDL-cholesterol/total plasma TG molar ratio: &#x0003e;0.69</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Apolipoprotein B (ApoB)/TC ratio: &#x0003c;0.15 g/mmol</p>
          </list-item>
          <list-item>
            <p>Non-HDL-C/apoB ratio: &#x0003e;4.91&#x02009;mmol/g</p>
          </list-item>
          <list-item>
            <p>ApoB &#x0003c;1.2 g/l, triglyceride at least 1.5 mmol/l, triglyceride/apoB &#x0003c;10 mmol/g, and TC/apoB at least 6.2&#x000a0;mmol/g</p>
          </list-item>
          <list-item>
            <p>Polyacrylamide gradient gel electrophoresis (PGGE)
<list list-type="bullet"><list-item><p>Quantitative stains for small VLDL and intermediate-density lipoprotein (IDL) with little or no LDL</p></list-item><list-item><p>Qualitative: Area under the curve IDL-range/LDL-range ratio &#x0003e;0.5</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>&#x003b2; quantification is also a valuable biochemical test for dysbetalipoproteinemia as it detects &#x0201c;&#x003b2;-VLDL&#x0201d; in the supernatant after ultracentrifugation and determines if the VLDL to triglyceride ratio is high.<xref ref-type="bibr" rid="article-20784.r22">[22]</xref>&#x000a0;Both features are hallmarks of the disease. However, these specialized tests are not widely available and cannot be practically&#x000a0;done in all patients with mixed hyperlipidemia. Using apoB as a ratio to total or non-HDL cholesterol or in a multi-step algorithm initially to determine if additional evaluation is indicated is also a promising approach. More comprehensive&#x000a0;implementation of diagnostic pathways using apo B could lead to the more rational use of specialized investigations and consistent detection of patients with dysbetalipoproteinemia. Therefore, many cases are likely to remain undiagnosed if a consistent, evidence-based approach to diagnosing dysbetalipoproteinemia is not utilized.</p>
      </sec>
      <sec id="article-20784.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of dysbetalipoproteinemia is a multistep approach combining lifestyle modifications and medical treatment. Dietary modifications are the primary component of lifestyle changes that have the most significant impact on patients with&#x000a0;dysbetalipoproteinemia.<xref ref-type="bibr" rid="article-20784.r30">[30]</xref></p>
        <p>
<bold>Lifestyle Modifications</bold>
</p>
        <p>The diet recommended for patients with FD generally consists of minimally processed, high-fiber, plant-based foods (eg, vegetables,&#x000a0; whole grains, legumes, and nuts) and has been found to improve hyperlipidemia in most patients.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530470/#B95-ijms-24-13942">95</ext-link>] Dietary changes should reduce saturated fat intake and instead consume unsaturated fats and long-chain polyunsaturated fatty acids.<xref ref-type="bibr" rid="article-20784.r32">[30]</xref><xref ref-type="bibr" rid="article-20784.r31">[31]</xref><xref ref-type="bibr" rid="article-20784.r32">[32]</xref>&#x000a0;Specific dietary modifications include increasing intake of lean proteins, vinegar, fish oil, tea, and cinnamon and reducing alcohol consumption and daily total calories. Patients should also be instructed to lose weight and increase their daily exercise, as weight reduction in these patients has led to lower triglyceride levels.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530470/#B95-ijms-24-13942">95</ext-link>]</p>
        <p>A low carbohydrate diet is also recommended, as concomitant insulin resistance is common among individuals with dysbetalipoproteinemia. Additionally, a diet low in carbohydrates has been associated with lower plasma lipid levels.<xref ref-type="bibr" rid="article-20784.r33">[33]</xref>&#x000a0;Evaluation and optimization of secondary risk factors, including hypothyroidism, type 2 diabetes mellitus, and metabolic syndrome, demonstrated improvement of triglyceride levels.<xref ref-type="bibr" rid="article-20784.r34">[34]</xref></p>
        <p>
<bold>Pharmacological Therapy</bold>
</p>
        <p>When dietary modifications are insufficient in optimizing lipid levels, statins with fibrates are the mainstay of therapy and demonstrate improvement in LDL levels. Clinicians should focus on non-HDL cholesterol as LDL-C is usually low.<xref ref-type="bibr" rid="article-20784.r34">[34]</xref>&#x000a0;Statin monotherapy leaves patients hypercholesterolemic, and adding fibrates improves lipid profiles.<xref ref-type="bibr" rid="article-20784.r35">[35]</xref></p>
        <p>There are limited randomized controlled trials specific for familial dysbetalipoproteinemia patients evaluating the effect of lipid-lowering medications. The completed trials did have indeterminate endpoints in terms&#x000a0;of on-target lipid levels. Overall trials did demonstrate a reduction in LDL and total cholesterol levels.<xref ref-type="bibr" rid="article-20784.r36">[36]</xref><xref ref-type="bibr" rid="article-20784.r37">[37]</xref><xref ref-type="bibr" rid="article-20784.r38">[38]</xref><xref ref-type="bibr" rid="article-20784.r39">[39]</xref>&#x000a0;The role of PCSK9 inhibitors remains unclear in FD. Some studies report that the dominant portion of apoB-containing lipoproteins is decreased with PCSK9 inhibition, such as LDL in mixed hyperlipidemia and hypercholesterolemia, and cholesterol-rich VLDL, remnants, and LDL in familial dysbetalipoproteinemia. PCSK9 inhibitors could be helpful in patients who are resistant or intolerant to statin or fibrate therapy.<xref ref-type="bibr" rid="article-20784.r40">[40]</xref></p>
      </sec>
      <sec id="article-20784.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis of dysbetalipoproteinemia remains broad as dyslipidemia and xanthomas can be present in other conditions, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Combined hyperlipidemia: ApoB levels are elevated with increases in both LDL and VLDL secondary to overproduction.<xref ref-type="bibr" rid="article-20784.r41">[41]</xref> Unlike dysbetalipoproteinemia, which does not have an increase in LDL-C.</p>
          </list-item>
          <list-item>
            <p>Nephrotic syndrome: Increases the production of all cholesterol variants.<xref ref-type="bibr" rid="article-20784.r42">[42]</xref></p>
          </list-item>
          <list-item>
            <p>Hepatic lipase deficiency: Deficiency in hepatic lipase activity is required for converting IDL to LDL. HDL is usually elevated as hepatic lipase manages the metabolism of HDL.<xref ref-type="bibr" rid="article-20784.r43">[43]</xref> Phenotypically presents similar to dysbetalipoproteinemia.</p>
          </list-item>
          <list-item>
            <p>Polygenic hypercholesterolemia</p>
          </list-item>
          <list-item>
            <p>Metabolic syndrome</p>
          </list-item>
          <list-item>
            <p>LPL deficiency</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Familial hypertriglyceridemia</p>
          </list-item>
        </list>
        <p>Familial dysbetalipoproteinemia can also be mistaken for familial hypercholesterolemia. Familial hypercholesterolemia is a genetic lipid disorder with defective LDL receptors, leading to increased LDL in the peripheral circulation. Usually, LDL cholesterol is low in these patients. However, they can sometimes be falsely elevated when the Friedwalds formula calculates LDL-C.&#x000a0;The Friedewald formula subtracts the cholesterol content in HDL and VLDL from the total cholesterol to estimate the fasting plasma concentration of LDL-C. Cholesterol in VLDL is estimated by dividing the total TG concentration by 5. However, in familial hypercholesterolemia, the cholesterol content in VLDL particles and remnants is increased, with the result that the Friedewald formula underestimates cholesterol in VLDL and overestimates cholesterol in LDL.<xref ref-type="bibr" rid="article-20784.r44">[44]</xref>&#x000a0;Evaluation of causes of xanthomas and xanthelasmas is also essential.</p>
      </sec>
      <sec id="article-20784.s9" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>The combination of fibrate and statin therapy is associated with an increased risk of myopathies. In dysbetalipoproteinemia, the benefits of combined statin-fibrate therapy would outweigh the risks associated with these medications. Patient education on the potential side effects of combination therapy is essential.<xref ref-type="bibr" rid="article-20784.r45">[45]</xref></p>
      </sec>
      <sec id="article-20784.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>When managed, patients with familial dysbetalipoproteinemia have a good prognosis. Commonly, patients respond well to lifestyle modifications and medical treatment. Patients with a higher level of triglyceride and total cholesterol have an increased risk for complications than those without elevated levels. Early diagnosis and treatment result in the best prognosis for patient longevity.&#x000a0;Remnant cholesterol is the abundant cholesterol in dysbetalipoproteinemia. Increased remnant cholesterol is causally associated with an increased risk of ischemic heart disease and is also associated&#x000a0;with a higher risk of all-cause mortality.<xref ref-type="bibr" rid="article-20784.r46">[46]</xref><xref ref-type="bibr" rid="article-20784.r47">[47]</xref></p>
      </sec>
      <sec id="article-20784.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of dysbetalipoproteinemia include the following:<xref ref-type="bibr" rid="article-20784.r48">[48]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Peripheral vascular disease</p>
          </list-item>
          <list-item>
            <p>Coronary artery disease</p>
          </list-item>
          <list-item>
            <p>Insulin resistance</p>
          </list-item>
          <list-item>
            <p>Acute pancreatitis&#x000a0;<xref ref-type="bibr" rid="article-20784.r49">[49]</xref></p>
          </list-item>
        </list>
        <p>In addition, a predisposition to atherosclerosis is noted. Early diagnosis and treatment will help manage complications.</p>
      </sec>
      <sec id="article-20784.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Lifestyle modifications are essential with a good dietician to guide therapy. Prompt medical assessment is also necessary to improve patient outcomes through early recognition of symptoms with the management of complications.&#x000a0;Patients do not understand that triglycerides are analyzed along with cholesterol. The possibility of complications should be made known to the patient of dysbetalipoproteinemia, emphasizing the increased risk of cardiovascular disease. Clinicians should advise patients that their condition responds well to simple dietary modifications, exercise, and weight loss interventions.<xref ref-type="bibr" rid="article-20784.r48">[48]</xref> A trained dietitian provides thorough diet instructions. Exercise counseling may be helpful in treating dyslipidemia and reducing the risk of symptomatic cardiovascular disease.&#x000a0;In addition, the clinician should stress the importance of alcohol intake of no more than 1 drink per day, provide instructions on the use of medications, and provide comprehensive diabetes education to diabetic patients.</p>
      </sec>
      <sec id="article-20784.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dysbetalipoproteinemia should be considered in all cases of abnormal lipid profiles. Phenotypic presentation is not always present. A high degree of suspicion is needed. Prompt evaluation with genetic testing will help guide therapy. The goal of treatment for familial dysbetalipoproteinemia patients is reducing non&#x02013;HDL-C. The prognosis can be improved with dietary therapy and treatment with a statin and fibrate combination. An interprofessional management approach includes primary care clinicians, specialists, mid-level practitioners (PA/NP), nursing staff, and pharmacists collaborating to improve patient outcomes.</p>
      </sec>
      <sec id="article-20784.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20784&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20784">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/dysbetalipoproteinemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20784">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20784/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20784">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20784.s15">
        <title>References</title>
        <ref id="article-20784.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidemann</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Koopal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baass</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Defesche</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Zuurbier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Roeters van Lennep</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Riksen</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Boot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Visseren</surname>
                <given-names>FLJ</given-names>
              </name>
            </person-group>
            <article-title>Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.</article-title>
            <source>Clin Genet</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>102</volume>
            <issue>4</issue>
            <fpage>253</fpage>
            <page-range>253-261</page-range>
            <pub-id pub-id-type="pmid">35781703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hopkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2005</year>
            <month>Apr</month>
            <day>05</day>
            <volume>45</volume>
            <issue>7</issue>
            <fpage>1003</fpage>
            <page-range>1003-12</page-range>
            <pub-id pub-id-type="pmid">15808755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahley</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rall</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes.</article-title>
            <source>J Lipid Res</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>1933</fpage>
            <page-range>1933-49</page-range>
            <pub-id pub-id-type="pmid">10552997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Recent insights into factors affecting remnant lipoprotein uptake.</article-title>
            <source>Curr Opin Lipidol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>218</fpage>
            <page-range>218-28</page-range>
            <pub-id pub-id-type="pmid">20463470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bennet</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Di Angelantonio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wensley</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dahlin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahlbom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Keavney</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wiman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Faire</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Danesh</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Association of apolipoprotein E genotypes with lipid levels and coronary risk.</article-title>
            <source>JAMA</source>
            <year>2007</year>
            <month>Sep</month>
            <day>19</day>
            <volume>298</volume>
            <issue>11</issue>
            <fpage>1300</fpage>
            <page-range>1300-11</page-range>
            <pub-id pub-id-type="pmid">17878422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siest</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pillot</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>R&#x000e9;gis-Bailly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leininger-Muller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Steinmetz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Galteau</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Visvikis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Apolipoprotein E: an important gene and protein to follow in laboratory medicine.</article-title>
            <source>Clin Chem</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>8 Pt 1</issue>
            <fpage>1068</fpage>
            <page-range>1068-86</page-range>
            <pub-id pub-id-type="pmid">7628082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smelt</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>de Beer</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.</article-title>
            <source>Semin Vasc Med</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>249</fpage>
            <page-range>249-57</page-range>
            <pub-id pub-id-type="pmid">15630634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dong</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Innerarity</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Newhouse</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Weisgraber</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity.</article-title>
            <source>J Lipid Res</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>1173</fpage>
            <page-range>1173-80</page-range>
            <pub-id pub-id-type="pmid">9643348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sampson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wolska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meeusen</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Donato</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Remaley</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol.</article-title>
            <source>Front Genet</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>935257</fpage>
            <pub-id pub-id-type="pmid">35910208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Beer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stalenhoef</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Hoogerbrugge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gevers Leuven</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>van Duijn</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Havekes</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Smelt</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --&#x0003e; Cys) homozygotes is associated with hyperinsulinemia.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2002</year>
            <month>Feb</month>
            <day>01</day>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>294</fpage>
            <page-range>294-9</page-range>
            <pub-id pub-id-type="pmid">11834531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LaRosa</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chambless</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Criqui</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Frantz</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Glueck</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Heiss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Patterns of dyslipoproteinemia in selected North American populations. The Lipid Research Clinics Program Prevalence Study.</article-title>
            <source>Circulation</source>
            <year>1986</year>
            <month>Jan</month>
            <volume>73</volume>
            <issue>1 Pt 2</issue>
            <fpage>I12</fpage>
            <page-range>I12-29</page-range>
            <pub-id pub-id-type="pmid">3940679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hopkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Nanjee</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>McGinty</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.</article-title>
            <source>Atherosclerosis</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>207</volume>
            <issue>2</issue>
            <fpage>559</fpage>
            <page-range>559-66</page-range>
            <pub-id pub-id-type="pmid">19524242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sniderman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>de Graaf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thanassoulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tremblay</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Couture</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of type III hyperlipoproteinemia.</article-title>
            <source>J Clin Lipidol</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>1383</fpage>
            <page-range>1383-1389</page-range>
            <pub-id pub-id-type="pmid">30318453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blom</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations.</article-title>
            <source>Clin Chem</source>
            <year>2005</year>
            <month>May</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>904</fpage>
            <page-range>904-7</page-range>
            <pub-id pub-id-type="pmid">15855667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Br&#x000fc;mmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Greten</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Beisiegel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia.</article-title>
            <source>J Mol Med (Berl)</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>76</volume>
            <issue>5</issue>
            <fpage>355</fpage>
            <page-range>355-64</page-range>
            <pub-id pub-id-type="pmid">9587070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chait</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brunzell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hazzard</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Type-III Hyperlipoproteinaemia ("remnant removal disease"). Insight into the pathogenetic mechanism.</article-title>
            <source>Lancet</source>
            <year>1977</year>
            <month>Jun</month>
            <day>04</day>
            <volume>1</volume>
            <issue>8023</issue>
            <fpage>1176</fpage>
            <page-range>1176-8</page-range>
            <pub-id pub-id-type="pmid">68276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koopal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Visseren</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-139</page-range>
            <pub-id pub-id-type="pmid">28098593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rothschild</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duhon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jetty</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goldenberg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Glueck</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pathognomonic Palmar Crease Xanthomas of Apolipoprotein E2 Homozygosity-Familial Dysbetalipoproteinemia.</article-title>
            <source>JAMA Dermatol</source>
            <year>2016</year>
            <month>Nov</month>
            <day>01</day>
            <volume>152</volume>
            <issue>11</issue>
            <fpage>1275</fpage>
            <page-range>1275-1276</page-range>
            <pub-id pub-id-type="pmid">27603268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nayak</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Images in clinical medicine. Eruptive xanthomas associated with hypertriglyceridemia and new-onset diabetes mellitus.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Mar</month>
            <day>18</day>
            <volume>350</volume>
            <issue>12</issue>
            <fpage>1235</fpage>
            <pub-id pub-id-type="pmid">15028827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sniderman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Thanassoulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Glavinovic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Navar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pencina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ference</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.</article-title>
            <source>JAMA Cardiol</source>
            <year>2019</year>
            <month>Dec</month>
            <day>01</day>
            <volume>4</volume>
            <issue>12</issue>
            <fpage>1287</fpage>
            <page-range>1287-1295</page-range>
            <pub-id pub-id-type="pmid">31642874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koopal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Retterst&#x000f8;l</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sjouke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hovingh</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Ros</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Graaf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dullaart</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Bertolini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Visseren</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.</article-title>
            <source>Atherosclerosis</source>
            <year>2015</year>
            <month>May</month>
            <volume>240</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-7</page-range>
            <pub-id pub-id-type="pmid">25768710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boot</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Luvai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neely</surname>
                <given-names>RDG</given-names>
              </name>
            </person-group>
            <article-title>The clinical and laboratory investigation of dysbetalipoproteinemia.</article-title>
            <source>Crit Rev Clin Lab Sci</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>7</issue>
            <fpage>458</fpage>
            <page-range>458-469</page-range>
            <pub-id pub-id-type="pmid">32255405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>A review of symptoms of coronary artery disease in women.</article-title>
            <source>J Adv Nurs</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-23</page-range>
            <pub-id pub-id-type="pmid">12074748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conte</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vale</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Peripheral Arterial Disease.</article-title>
            <source>Heart Lung Circ</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>427</fpage>
            <page-range>427-432</page-range>
            <pub-id pub-id-type="pmid">29150158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marais</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Blom</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E.</article-title>
            <source>Crit Rev Clin Lab Sci</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-62</page-range>
            <pub-id pub-id-type="pmid">24405372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Utermann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hees</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steinmetz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man.</article-title>
            <source>Nature</source>
            <year>1977</year>
            <month>Oct</month>
            <day>13</day>
            <volume>269</volume>
            <issue>5629</issue>
            <fpage>604</fpage>
            <page-range>604-7</page-range>
            <pub-id pub-id-type="pmid">199847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kataoka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paidi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>BV</given-names>
              </name>
            </person-group>
            <article-title>Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype.</article-title>
            <source>Clin Chem</source>
            <year>1994</year>
            <month>Jan</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-3</page-range>
            <pub-id pub-id-type="pmid">8287516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalil</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Rab&#x000e8;s</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Boileau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Varret</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>APOE gene variants in primary dyslipidemia.</article-title>
            <source>Atherosclerosis</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>328</volume>
            <fpage>11</fpage>
            <page-range>11-22</page-range>
            <pub-id pub-id-type="pmid">34058468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hopkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Nanjee</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Hyperlipoproteinemia type 3: the forgotten phenotype.</article-title>
            <source>Curr Atheroscler Rep</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>440</fpage>
            <pub-id pub-id-type="pmid">25079293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yanai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Adachi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hakoshima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Katsuyama</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Sep</month>
            <day>11</day>
            <volume>24</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">37762244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morganroth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Fredrickson</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>The biochemical, clinical, and genetic features of type III hyperlipoproteinemia.</article-title>
            <source>Ann Intern Med</source>
            <year>1975</year>
            <month>Feb</month>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>158</fpage>
            <page-range>158-74</page-range>
            <pub-id pub-id-type="pmid">163608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Authors/Task Force Members:</collab>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Drexel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoes</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Jennings</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>&#x0017d;</given-names>
              </name>
              <name>
                <surname>Riccardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Taskinen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tokgozoglu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Verschuren</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Vlachopoulos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention &#x00026; Rehabilitation (EACPR).</article-title>
            <source>Atherosclerosis</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>253</volume>
            <fpage>281</fpage>
            <page-range>281-344</page-range>
            <pub-id pub-id-type="pmid">27594540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Retterst&#x000f8;l</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hennig</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Iversen</surname>
                <given-names>PO</given-names>
              </name>
            </person-group>
            <article-title>Improved plasma lipids and body weight in overweight/obese patients with type III hyperlipoproteinemia after 4 weeks on a low glycemic diet.</article-title>
            <source>Clin Nutr</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-5</page-range>
            <pub-id pub-id-type="pmid">19232793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riccardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vaccaro</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Costabile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rivellese</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>How Well Can We Control Dyslipidemias Through Lifestyle Modifications?</article-title>
            <source>Curr Cardiol Rep</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>66</fpage>
            <pub-id pub-id-type="pmid">27216846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Illingworth</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>O'Malley</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.</article-title>
            <source>Metabolism</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>403</fpage>
            <page-range>403-9</page-range>
            <pub-id pub-id-type="pmid">2182974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Smelt</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Leuven</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Vroom</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>van der Laarse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van 't Hooft</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.</article-title>
            <source>Am J Med</source>
            <year>1994</year>
            <month>Jan</month>
            <volume>96</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-56</page-range>
            <pub-id pub-id-type="pmid">8304363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gylling</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Relas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miettinen</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Postprandial vitamin A and squalene clearances and cholesterol synthesis off and on lovastatin treatment in type III hyperlipoproteinemia.</article-title>
            <source>Atherosclerosis</source>
            <year>1995</year>
            <month>May</month>
            <volume>115</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-26</page-range>
            <pub-id pub-id-type="pmid">7669084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawashiri</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nohara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Noguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Inazu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mabuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamagishi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.</article-title>
            <source>Clin Chim Acta</source>
            <year>2011</year>
            <month>May</month>
            <day>12</day>
            <volume>412</volume>
            <issue>11-12</issue>
            <fpage>1068</fpage>
            <page-range>1068-75</page-range>
            <pub-id pub-id-type="pmid">21354122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishigami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hiraoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsuzawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.</article-title>
            <source>Atherosclerosis</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>168</volume>
            <issue>2</issue>
            <fpage>359</fpage>
            <page-range>359-66</page-range>
            <pub-id pub-id-type="pmid">12801620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waldmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Busygina</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Altenhofer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Henze</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Folwaczny</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parhofer</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).</article-title>
            <source>PLoS One</source>
            <year>2022</year>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>e0265838</fpage>
            <pub-id pub-id-type="pmid">35320320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bello-Chavolla</surname>
                <given-names>OY</given-names>
              </name>
              <name>
                <surname>Kuri-Garc&#x000ed;a</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>R&#x000ed;os-R&#x000ed;os</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vargas-V&#x000e1;zquez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cort&#x000e9;s-Arroyo</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tapia-Gonz&#x000e1;lez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cruz-Bautista</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aguilar-Salinas</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>FAMILIAL COMBINED HYPERLIPIDEMIA: CURRENT KNOWLEDGE, PERSPECTIVES, AND CONTROVERSIES.</article-title>
            <source>Rev Invest Clin</source>
            <year>2018</year>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>224</fpage>
            <page-range>224-236</page-range>
            <pub-id pub-id-type="pmid">30307446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seeger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fehr</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Nephrotic Syndrome in Adult Patients--Etiology and Complications].</article-title>
            <source>Praxis (Bern 1994)</source>
            <year>2016</year>
            <month>Mar</month>
            <day>02</day>
            <volume>105</volume>
            <issue>5</issue>
            <fpage>259</fpage>
            <page-range>259-67</page-range>
            <pub-id pub-id-type="pmid">26934010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connelly</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Hepatic lipase deficiency.</article-title>
            <source>Crit Rev Clin Lab Sci</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>547</fpage>
            <page-range>547-72</page-range>
            <pub-id pub-id-type="pmid">9885775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedewald</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Fredrickson</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.</article-title>
            <source>Clin Chem</source>
            <year>1972</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>499</fpage>
            <page-range>499-502</page-range>
            <pub-id pub-id-type="pmid">4337382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrill</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Statin-fibrate combination therapy.</article-title>
            <source>Ann Pharmacother</source>
            <year>2001</year>
            <season>Jul-Aug</season>
            <volume>35</volume>
            <issue>7-8</issue>
            <fpage>908</fpage>
            <page-range>908-17</page-range>
            <pub-id pub-id-type="pmid">11485144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varbo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tybj&#x000e6;rg-Hansen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Frikke-Schmidt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Remnant cholesterol as a causal risk factor for ischemic heart disease.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>427</fpage>
            <page-range>427-436</page-range>
            <pub-id pub-id-type="pmid">23265341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varbo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freiberg</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population.</article-title>
            <source>Clin Chem</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>533</fpage>
            <page-range>533-43</page-range>
            <pub-id pub-id-type="pmid">25605681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marais</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Dysbetalipoproteinemia: an extreme disorder of remnant metabolism.</article-title>
            <source>Curr Opin Lipidol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>292</fpage>
            <page-range>292-7</page-range>
            <pub-id pub-id-type="pmid">26103610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20784.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pedersen</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Langsted</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis.</article-title>
            <source>JAMA Intern Med</source>
            <year>2016</year>
            <month>Dec</month>
            <day>01</day>
            <volume>176</volume>
            <issue>12</issue>
            <fpage>1834</fpage>
            <page-range>1834-1842</page-range>
            <pub-id pub-id-type="pmid">27820614</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
